Commission Implementing Decision (EU) 2025/362 of 21 February 2025 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance)
Grade B
mapped from publisher markup. A grade says how a document's structure was obtained, not how reliable the law is.
Address https://gelex.eu/eli/EU/decision/2025/362@2025-02-21/en
THE EUROPEAN COMMISSION,
Having regard to the Treaty on the Functioning of the European Union,
Having regard to Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products, and in particular Article 14(5) thereof,
After consulting the Standing Committee on Biocidal Products,
Whereas:
(1) Cypermethrin was approved as an active substance for use in biocidal products of product-type 8 by Commission Implementing Regulation (EU) No 945/2013 subject to the conditions set out in the Annex to that Regulation.
(2) The approval of cypermethrin for use in biocidal products of product-type 8 (the approval) is to expire on 31 May 2025. On 24 November 2023, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval (the application).
(3) On 22 May 2024, the evaluating competent authority of Belgium informed the Commission that it had decided, pursuant to Article 14(1) of Regulation (EU) No 528/2012, that a full evaluation of the application was necessary. Pursuant to Article 8(1) of that Regulation, the evaluating competent authority is to perform a full evaluation of the application within 365 days of its validation.
(4) The evaluating competent authority may, as appropriate, require the applicant to provide sufficient data to carry out the evaluation, in accordance with Article 8(2) of Regulation (EU) No 528/2012. In that event, the 365-day period is suspended for a period that may not exceed 180 days in total unless a longer suspension is justified by the nature of the data requested or by exceptional circumstances.
(5) Within 270 days of receipt of a recommendation from the evaluating competent authority, the European Chemicals Agency is to prepare and submit to the Commission an opinion on renewal of the approval of the active substance in accordance with Article 14(3) of Regulation (EU) No 528/2012.
(6) Consequently, for reasons beyond the control of the applicant, the approval is likely to expire before a decision has been taken on its renewal. It is therefore appropriate to postpone the expiry date of the approval for a period of time sufficient to enable the examination of the application. Taking into account the time-limits for evaluation by the evaluating competent authority, for preparation and submission by the European Chemicals Agency of its opinion and the time needed for the Commission to decide whether to renew the approval, the expiry date should be postponed to 30 November 2027.
(7) After the postponement of the expiry date of the approval, cypermethrin remains approved for use in biocidal products of product-type 8 subject to the conditions set out in the Annex to Implementing Regulation (EU) No 945/2013,
HAS ADOPTED THIS DECISION:
Article 1
The expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 set out in the Annex to Implementing Regulation (EU) No 945/2013 is postponed to 30 November 2027.
Article 2
This Decision shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Done at Brussels, 21 February 2025. For the Commission The President Ursula von der Leyen
Versions
Cited by
- Commission Implementing Decision (EU) 2026/1113 of 22 May 2026 repealing Implementing Decision (EU) 2025/362 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance) Decision · Grade B
Pursuant to Commission Implementing Decision (EU) 2025/362 the expiry date of the approval was postponed to 30 November 2027, to allow sufficient time for the examination of the application.
- Commission Implementing Decision (EU) 2026/1113 of 22 May 2026 repealing Implementing Decision (EU) 2025/362 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance) Decision · Grade B
However, on 21 May 2025, the applicant who submitted the application informed the Commission that it withdrew its application for the renewal of approval. Consequently, as it has not been established that cypermethrin still meets the conditions laid down in Article 4(1) of Regulation (EU) No 528/2012, Commission Implementing Decision (EU) 2026/1112 did not renew the approval. Therefore, it is appropriate to repeal Implementing Decision (EU) 2025/362 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8,
- Commission Implementing Decision (EU) 2026/1113 of 22 May 2026 repealing Implementing Decision (EU) 2025/362 postponing the expiry date of the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance) Decision · Grade B
Implementing Decision (EU) 2025/362 is repealed.
- Commission Implementing Decision (EU) 2026/1112 of 22 May 2026 not renewing the approval of cypermethrin for use in biocidal products of product-type 8 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council (Text with EEA relevance) Decision · Grade B
Commission Implementing Decision (EU) 2025/362 postponed the expiry date of the approval to 30 November 2027 in order to allow sufficient time for the examination of the application for renewal.